Clinical Trial Update: PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a PARP inhibitor combined with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy in patients with neuroendocrine tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 177Lu-DOTA-Octreotate (177Lu-DOTA-Octreotate)
• PARP inhibitor

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Neuroendocrine Tumors | Phase 1 | Status: RECRUITING